Search

Displaying results 231 - 240 of 2482 in total
  1. Drug

    Enfortumab vedotin

    go.drugbank.com/drugs/DB13007
    ApprovedInvestigational

    The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    Muparfostat

    go.drugbank.com/drugs/DB05808
    Investigational

    Muparfostat (PI-88) is a mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic

    Synonyms: Heparanase inhibitor PI-88
  3. Drug

    Benzonatate

    go.drugbank.com/drugs/DB00868
    Approved

    Benzonatate is an oral antitussive drug used in the relief and suppression of cough in patients older than ten years of age.

    Synonyms: nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate, p-butylaminobenzoic acid ω-O-methylnonaethyleneglycol ester
  4. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.

  5. Drug

    Potassium bicarbonate

    go.drugbank.com/drugs/DB11098
    ApprovedInvestigational

    Potassium bicarbonate is a white, crystalline, slightly alkaline and salty substance. It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid. It is registered...

  6. Drug

    AZD-8186

    go.drugbank.com/drugs/DB15029
    Investigational

    AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot

  7. Target

    Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1

    go.drugbank.com/bio_entities/BE0018277
    TargetHumans

    Functional component of the Nogo receptor signaling complex (RTN4R/NGFR) in RhoA activation responsible for some inhibition of axonal regeneration by myelin-associated factors (PubMed:14966521, PubMed:15694321). Is also an important nega...

    Polypeptides: Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1Synonyms: Leucine-rich repeat neuronal protein 1, Leucine-rich repeat neuronal protein 6A
  8. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    Mirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). NF1 is an autosomal-dominant genetic condit...

    Synonyms: PD 0325901, PD-0325901Categories: P-glycoprotein substrates
  9. Drug

    Aluminum chlorohydrex propylene glycol

    go.drugbank.com/drugs/DB11208
    Approved

    Aluminum chlorohydrex propylene glycol is a complex consisting of Aluminum Chorohydrate and propylene glycol (PG).

  10. Drug

    Vamotinib

    go.drugbank.com/drugs/DB15396
    Investigational

    Vamotinib (PF-114) is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With … Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene).